Ovid Therapeutics Q3 2026 earnings
Q3 2026 net loss of $20.8 million widened from $12.2 million in Q3 2025, driven by increased R&D spending supporting clinical programs.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| EPS (GAAP) | $-0.10 | +41.2% | — | Ex. 99.1, income statement |
Revenue breakdown
not stated in the 8-K
Margins and costs
- Gross margin not stated in the 8-K
- Operating expenses $22.4 million (+76.7% YoY)
- One-offs in the quarter not stated in the 8-K
- Effective tax rate not stated in the 8-K
- Non-GAAP bridge not stated in the 8-K
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Cash, cash equivalents and marketable securities | $161.4 million | $90.4 million | — | +78.6% |
| Working capital | $130.1 million | $66.1 million | — | +96.8% |
| Total assets | $222.2 million | $150.9 million | — | +47.2% |
Guidance
not stated in the 8-K
What drove it
- Revenue story Total revenue of $132,000 increased 13.3% year-over-year, driven by license and other revenue of $132,000.
- EPS story Net loss per share of $0.10 widened year-over-year despite a 41.2% reduction in the loss per share, driven by increased operating expenses.
- One-off check not stated in the 8-K
The good
- Cash and equivalents increased to $161.4 million as of September 30, 2026.
- License and other revenue of $132,000 grew year-over-year.
The bad
- Research and development expenses increased 167.3% year-over-year to $15.7 million.
- Net loss widened 70.1% year-over-year to $20.8 million.
The ugly
- none
Open questions
- The filing does not provide a reconciliation of GAAP net loss to adjusted net loss.
- The filing does not provide a reconciliation of GAAP EPS to adjusted EPS.
Full release
Ovid Therapeutics (OVID) earnings release, November 10, 2026
Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results
• OV329 is advancing in a global, Phase 2 focal epilepsy study expected to read out in H2 2027
• Ovid is enrolling patients in ongoing photosensitivity study intended to demonstrate the anticonvulsant effect of OV329; results expected in early 2027
• OV4071, the first-ever oral KCC2 direct activator, continues to progress in a Phase 1 single- and multiple-ascending dose study; translational ketamine challenge study ready for initiation
• Advancement of a pediatric formulation of OV329 is on track and Company plans to initiate a study in TSC-associated seizures before year-end 2026, representing the first indication in a broad potential DEE franchise
• Cash, cash equivalents and marketable securities were $161.4 million as of September 30, 2026; expected financial runway into 2029
NEW YORK, November 10, 2026 – Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the third quarter ended September 30, 2026.
“The third quarter was focused on execution toward multiple, near-term clinical milestones across our pipeline,” said Meg Alexander, President and Chief Executive Officer. “We anticipate findings from two high potential programs in early 2027, which may respectively demonstrate the broad potential of KCC2 direct activation and the anticonvulsant profile of OV329, a next-generation GABA-AT inhibitor. In addition to focal epilepsy, we are excited to start characterizing OV329 in specific developmental epileptic encephalopathies for which there is significant need, and the current treatments are limited. We intend to initiate the first DEE study in patients living with TSC before year-end. With strengthened clinical operations and capital to support upcoming milestones, Ovid is well positioned to deliver on our priorities and advance better, gentler medicines.”
PIPELINE AND BUSINESS UPDATES
OV329, a next-generation GABA-AT inhibitor
Ovid is advancing OV329, a next-generation GABA-aminotransferase (GABA-AT) inhibitor, in several proof-of-concept studies designed to establish the drug's clinical potential across multiple adult and pediatric seizure disorders. OV329's mechanism of action was previously validated in multiple seizure disorders. Building upon robust cortical inhibition results that were established in human healthy volunteers, which were comparable with the effect of therapeutic doses of an established reference medicine (vigabatrin), the Company believes OV329 may confer benefit in multiple adult and pediatric indications, including treatment-resistant focal epilepsy (FE), tuberous sclerosis complex (TSC)-associated seizures and infantile spasms (IS) as well as other developmental epileptic encephalopathies (DEEs). OV329 is currently in, or is initiating three proof-of-concept and proof-of-anticonvulsant effect studies:
Adult focal epilepsy
• A Phase 2 global, randomized-placebo controlled study in treatment-resistant FE is actively enrolling:
This study is evaluating the efficacy, safety, and tolerability of OV329 at a dose of 7 mg in people living with treatment-resistant FE. This global study is designed with registrational-level rigor to potentially support multiple future seizure indications for OV329 and future labeling. The study is anticipated to be completed in the second half of 2027.
• Photosensitivity study enrolling:
Ovid initiated a photo paroxysmal response (PPR) study to evaluate the anticonvulsant effect of OV329 at 7 mg, allowing for testing of additional doses at levels above and below. The study is enrolling, and Ovid anticipates reading out topline data in the first quarter of 2027.
Developmental epileptic encephalopathies
Ovid is developing a distinct pediatric formulation of OV329, appropriate for use in clinical trials for infants and children. This granule formulation can be dosed based upon the patient's weight and mixed into solid foods and liquids, which is preferred by the patient and caregiver communities. This formulation is essential to unlocking what may be a potential franchise of selective DEE indications for OV329, where this mechanism of action has been previously established.
• Proof-of-concept study in TSC-associated seizures on track:
A safety and signal-finding study in patients with TSC-associated seizures is on track for initiation in the fourth quarter of 2026 with necessary regulatory clearances in process. The open-label trial is additionally intended to confirm the Company's pharmacology and dosing strategy for younger pediatric patients.
• Safety and signal-finding study in IS planned for 2027:
Ovid plans for a safety and signal-finding study of OV329 in patients with IS, which will be initiated following several cohorts of the above-mentioned TSC study.
KCC2 direct activator portfolio
Ovid is the only publicly traded company pioneering direct activators of the potassium-chloride cotransporter2 (KCC2). Existing and emerging pharmacodynamic data suggest that directly activating
KCC2 may convey broad therapeutic activity. Extensive pharmacology studies have been conducted with Ovid's current lead clinical KCC2 direct activator, OV4071, and the prior tool compound, OV350. Collectively, these studies suggest activating KCC2 has broad antipsychotic effects, in addition to demonstrating compelling signals of activity in animal pharmacodynamic models of Rett syndrome, seizures, chronic stress and anxiety models.
OV4071, the first-ever direct activator of KCC2... (truncated)erapeutic doses of reference drugs in the majority of animal models tested, including clozapine, risperidone, haloperidol, xenomaline trospium, and pimavanserin, among others. At relevant pharmacodynamic doses, Ovid's direct activators appear to be well-tolerated with no sedation.
The Company believes that activating KCC2 may have broad activity and is advancing both OV4071 and development candidates through its KCC2 discovery engine. The following clinical programs are underway:
• Phase 1 study of OV4071; topline results expected in the first quarter of 2027:
Ovid is actively evaluating OV4071 via staggered single and multiple ascending dose cohorts in an ongoing Phase 1 study in healthy volunteers, followed by an elderly healthy volunteer cohort. The Phase 1 study is intended to characterize the safety, tolerability, pharmacokinetics and exploratory electrophysiology to detect a potential proof-of-activity. There have been no serious adverse events in the Phase 1 trial to date after multiple single- and multiple-ascending dose cohorts. Ovid anticipates reading out topline data in the first quarter of 2027.
• Translational ketamine challenge study:
Ovid is ready for initiation of a ketamine challenge study of OV4071, which is designed to further characterize potential pharmacodynamic effects and proof-of-mechanism of KCC2 direct activation using a broad battery of electrophysiological biomarkers. Results are expected in the first quarter of 2027. Results from the Phase 1 and this translational ketamine challenge study could provide support for entering later stage proof-of-concept studies to establish potential therapeutic utility in multiple psychosis indications, including our first planned Phase 2 study in acute schizophrenia in 2027.
• KCC2 portfolio expansion; advancing next-generation compounds to support broad central nervous system (CNS) therapeutic potential:
Based upon the broad pharmacodynamic activity that has been established with OV4071 and OV350, Ovid is advancing a discovery engine focused on identifying additional novel KCC2 direct activator molecules. The Company is prioritizing molecules that are amenable to oral and injectable administration and moving them into IND-enabling studies. The Company is developing multiple, unique molecules with differentiated therapeutic profiles and formulations for potential conditions including a range of psychoses, behavioral, neurodegenerative and neurodevelopmental disorders.
BUSINESS STRATEGY AND CORPORATE UPDATES
Potential monetization of soticlestat interests:
As previously announced, Ovid and Takeda assigned global rights in soticlestat to a new company launched by Perceptive Advisors. Under the agreement, Ovid is eligible to receive up to $294.5 million in potential clinical, regulatory and commercial milestone payments, a portion of which is payable to Ligand Pharmaceuticals, and may also receive low- to mid-single-digit royalties on net sales if soticlestat is commercialized.
Third Quarter 2026 Financial Results
• Cash, cash equivalents and marketable securities as of September 30, 2026 totaled $161.4 million.
• Research and development expenses were $15.7 million for the third quarter ended September 30, 2026, compared to $5.9 million for the same period in 2025. The increase is primarily related to elevated preclinical and clinical study activities supporting the OV329 and OV4071 programs.
• General and administrative expenses were $6.7 million for the third quarter ended September 30, 2026, as compared to $6.8 million for the same period in 2025. The decrease between the periods was comprised of lower accounting and audit, legal, business development and other professional fees, offset by recognition of approximately $0.8 million of severance and talent acquisition costs in the quarter ended September 30, 2026.
• Total operating expenses were $22.4 million for the third quarter ended September 30, 2026, as compared to $12.7 million for the same period in 2025.
• Ovid reported a net loss of $20.8 million, or basic and diluted net loss per share attributable to common stockholders of $0.10, for the three months ended September 30, 2026, as compared to a net loss of $12.2 million, or basic and diluted net loss per share attributable to common stockholders of $0.17, for the same period in 2025.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to pioneering better, gentler medicines for the brain. The Company discovers and develops differentiated, small molecule medicines for neurological and neuropsychiatric disorders with significant unmet need. Ovid is developing: OV329, a next-generation GABA-AT inhibitor, as a potential therapy for treatment-resistant FE and DEEs, including TSC and IS; and OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit www.ovidrx.com.
Financial statements
Income Statement
For The Three Months Ended September 30, 2026 — Unaudited (in thousands, except share and per share data)
| For The Three Months Ended September 30, 2026 | For The Three Months Ended September 30, 2025 | |
|---|---|---|
| License and other revenue | 132 | |
| Total revenue | 132 | |
| Operating expenses: | ||
| Research and development | 15,695 | 5,870 |
| General and administrative | 6,669 | 6,785 |
| Total operating expenses | 22,364 | 12,655 |
| Loss from operations | -22,364 | -12,523 |
| Other income (expense), net | 1,584 | 365 |
| Loss before provision for income taxes | -20,780 | -12,158 |
| Net loss | -20,780 | -12,158 |
| Net loss per share of Series A preferred stock, basic and diluted | -168.01 | |
| Weighted-average Series A preferred stock shares outstanding, basic and diluted | 1,250 | |
| Net loss per share of common stock, basic and diluted | -0.1 | -0.17 |
| Weighted-average common stock shares outstanding, basic and diluted | 203,021,564 | 71,114,181 |
Balance Sheet
September 30, 2026 — Unaudited (in thousands)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| Cash, cash equivalents and marketable securities | 161,420 | 90,447 |
| Working capital(1) | 130,100 | 66,080 |
| Total assets | 222,244 | 150,934 |
| Total stockholders’ equity | 198,671 | 130,660 |
| (1)Working capital defined as current assets less current liabilities | (1)Working capital defined as current assets less current liabilities | (1)Working capital defined as current assets less current liabilities |
Cash Flow
From the 10-Q · Nine Months Ended September 30, 2026 — (unaudited) (in thousands)
| Nine Months Ended September 30, 2026 | Nine Months Ended September 30, 2025 | |
|---|---|---|
| Net loss | -52,777 | -27,077 |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Change in fair value of royalty monetization liability | 872 | |
| Noncash consideration received in licensing agreement transaction | -733 | |
| Unrealized loss on equity investment | 66 | |
| Change in accrued interest and accretion of discount on marketable securities | -1,307 | -433 |
| Stock-based compensation expense | 3,753 | 3,612 |
| Depreciation and amortization expense | 66 | 256 |
| Noncash operating lease expense | 954 | 882 |
| Change in lease liability | -1,065 | -994 |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | -624 | -356 |
| Accounts payable | 3,900 | -1,480 |
| Accrued expenses | -409 | -3,120 |
| Deferred revenue | 718 | |
| Net cash used in operating activities | -47,370 | -27,926 |
| Cash flows from investing activities: | ||
| Purchase of marketable securities | -110,639 | -14,792 |
| Sales/maturities of marketable securities | 41,000 | 37,000 |
| Net cash (used in) provided by investing activities | -69,639 | 22,208 |
| Cash flows from financing activities: | ||
| Proceeds from sale of shares of common stock and pre-funded warrants, net of expenses | 56,183 | |
| Proceeds from exercise of Series A warrants into shares of common stock and pre-funded warrants, net of expenses | 50,521 | |
| Proceeds from sales of shares of common stock under Cowen ATM program, net of expenses | 10,490 | |
| Proceeds from exercise of options and employee stock purchase plan | 667 | 28 |
| Net cash provided by financing activities | 117,861 | 28 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -194 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 658 | -5,690 |
Forward-Looking Statements... (truncated)estone payments and royalties upon success; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plan,” “potentially,” and “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, impediments to Ovid’s ability to achieve expected benefits of cost-savings efforts, risks related to Ovid’s ability to achieve its financial objectives, and the risk that Ovid may not be able to realize the intended benefits of its business strategy. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption “Risk Factors” in Ovid’s most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”), and in subsequent and future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Condensed Consolidated Statements of Operations
Unaudited
Select Condensed Consolidated Balance Sheet Data
Unaudited
Contact
Investor Relations & Media
Investors@ovidrx.com
202.361.0445